Rgenix is a privately-held clinical-stage biopharmaceutical company developing first-in-class drugs that target key pathways in cancer progression.

310 E 67th St, Suite 1-12‎ New York, NY
(646) 856-9261
info@rgenix.com

Jue Pu

Jue leads the cancer biomarker and liquid biopsy research and development at Lepu Medical. She also leads international investment for Lepu Medical, with successful investments including Viralytics (acquired by Merck). Jue holds a Master of Science degree in Materials Science Engineering at Stanford University. She holds a dual undergraduate degree, summa cum laude, from the Wharton School of Finance and Materials Science Engineering at the University of Pennsylvania.